My favorite statement in the PR is calling out Dr
Post# of 153875
(Total Views: 549)
Posted On: 09/29/2021 10:03:07 AM
My favorite statement in the PR is calling out Dr Patentson yet again more than once.
Cytodyn company quote:
It is clearly a direct conflict of interest for Dr. Bruce Patterson to continuously seek to force a relationship between IncellDx and CytoDyn while trying to gain a seat on the Board of Directors of CytoDyn.
I came to the same conclusion when Dr. Patenson stated in their last limited meeting… implying that when they take over as the BOD and have control of Cytodyn they would prefer to do research and development in house.
I take this statement as they would buy IncellDX yet again after Rosenbaum said clearly and exuberantly said that they would not purchase IncellDX. How else would they do “ in house R&D”. Rosenbaum and Patenson do not seem aligned in the future relationship of IncellDX. Therefore we should be worried about this. This is not something as investors we want. We have a small but effective lab that Dr. Recknor has put together for our company already doing all we need.
I am also happy that they have answered the 13d lack of experience in financing that they have been pushing. No experience on their part is a high risk for shareholder.
Even now we will have to authorize more shares at this year’s shareholders meeting. We may have some small revenue but authorizing more shares will be needed to buy a boat load more of Leronlimab from Samsung and securing our place in line to manufacture the amount we need for the immediate future. Everyone should be aware of the need for money to guarantee manufacturing This is a giant step in our future sales to receive a large amount of doses hopefully before the end of this year.
Everyone realizes how close we are to EUA approvals right? This year we should accomplish these biotech milestone approvals. This is what I believe.
#goleronlimab
Cytodyn company quote:
It is clearly a direct conflict of interest for Dr. Bruce Patterson to continuously seek to force a relationship between IncellDx and CytoDyn while trying to gain a seat on the Board of Directors of CytoDyn.
I came to the same conclusion when Dr. Patenson stated in their last limited meeting… implying that when they take over as the BOD and have control of Cytodyn they would prefer to do research and development in house.
I take this statement as they would buy IncellDX yet again after Rosenbaum said clearly and exuberantly said that they would not purchase IncellDX. How else would they do “ in house R&D”. Rosenbaum and Patenson do not seem aligned in the future relationship of IncellDX. Therefore we should be worried about this. This is not something as investors we want. We have a small but effective lab that Dr. Recknor has put together for our company already doing all we need.
I am also happy that they have answered the 13d lack of experience in financing that they have been pushing. No experience on their part is a high risk for shareholder.
Even now we will have to authorize more shares at this year’s shareholders meeting. We may have some small revenue but authorizing more shares will be needed to buy a boat load more of Leronlimab from Samsung and securing our place in line to manufacture the amount we need for the immediate future. Everyone should be aware of the need for money to guarantee manufacturing This is a giant step in our future sales to receive a large amount of doses hopefully before the end of this year.
Everyone realizes how close we are to EUA approvals right? This year we should accomplish these biotech milestone approvals. This is what I believe.
#goleronlimab
(8)
(0)